1044871-04-6

Basic information

• Product Name: 2-{3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,7-dimethoxy-3,4-dihydroquinazolin-4-one
• Synonyms: 2-{3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,7-dimethoxy-3,4-dihydroquinazolin-4-one
• CAS NO: 1044871-04-6
• Molecular Weight: 423.512
• Mol File: 1044871-04-6.mol

Chemical Properties

• Boiling Point: 612.6±65.0 °C(Predicted)
• Density: 1.25±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-{3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,7-dimethoxy-3,4-dihydroquinazolin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,7-dimethoxy-3,4-dihydroquinazolin-4-one(1044871-04-6)
• EPA Substance Registry System: 2-{3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,7-dimethoxy-3,4-dihydroquinazolin-4-one(1044871-04-6)

Safety Data

• Hazardous Substances Data: 1044871-04-6(Hazardous Substances Data)

Usage

Quinazolinone Ring

Forms the core structure of the molecule

Functional Groups

Methoxy Groups (–OCH3): Attached to carbons 5 and 7 of the quinazolinone ring
3,5-Dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl Group: Attached to carbon 2 of the quinazolinone ring
Pyrrolidin-1-yl Group (-C4H8N): Part of the ethoxyphenyl group, suggesting potential interactions with biological systems

Biological Interaction

Potential interactions due to the presence of the pyrrolidin-1-yl group

Pharmacological Activity

May possess pharmacological properties

Medicinal Chemistry Interest

Could be of interest for medicinal chemistry research, potentially for drug development and discovery

Upstream product

• 10272-07-8 3.5-dimethoxyaniline 
• 40891-33-6 3,5-dimethoxyaniline hydrochloride 
• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 134-96-3 syringic aldehyde 
• 21544-81-0 4,6-dimethoxyindoline-2,3-dione 
• 1039310-14-9 3,5-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-benzaldehyde 
• 63920-73-0 2-amino-4,6-dimethoxybenzamide 

Relevant articles and documents

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.